clinical trial · NCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Novo Nordisk A/S·phase2·active not recruiting·n = 142
Diabetes Mellitus, Type 2Diabetic Peripheral NeuropathyCagriSema (Cagrilintide B and Semaglutide I)Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
brief summary
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
started
Jan 29, 2025
primary completion
Aug 21, 2026
completion
Aug 21, 2026
last updated
Dec 5, 2025
official title
Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol